Ewelina Kazimierczyk, Milena Dąbrowska, Marek Gierlotka, Katarzyna Kapica-Topczewska, Bartosz Karaszewski, Adam Kobayashi, Zbigniew Krasiński, Jacek Kubica, Alina Kułakowska, Krzysztof Kurek, Robert Ładny, Eliza Pleban, Konrad Rejdak, Grażyna Rydzewska, Agnieszka Słowik, Piotr Szopiński, Arkadiusz Woźniak, Agnieszka Tycińska
Andexanet alfa (AA) is a recombinant, inactive analog of human factor Xa (FXa), effectively reversing the effects of its inhibitors - rivaroxaban and apixaban, which are available in Poland. The drug was granted registration after the publication of the ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors 4), in which its efficacy in restoring hemostasis in life-threatening hemorrhages in a group of patients using the aforementioned anticoagulants was proven. Hence, AA is now recommended for patients receiving apixaban or rivaroxaban therapy with massive and uncontrollable hemorrhages, including hemorrhagic strokes (HS) and gastrointestinal bleeding...
January 17, 2024: Kardiologia Polska